ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0021167

myositis disease

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. myositis disease. Diseases, record MONDO_0021167. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021167

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
myositis disease
Open Targets
Open Targets ID
MONDO_0021167
Open Targets
Other names
Focal Myositides, Focal Myositis, IDIOPATHIC INFLAMM MYOPATHIES, INFECT MYOSITIS, INFLAMM MUSCLE DIS, INFLAMM MYOPATHIES IDIOPATHIC, INFLAMM MYOPATHY, Idiopathic Inflammatory Myopathies, Idiopathic Inflammatory Myopathy, Infectious Myositides, Infectious Myositis, Inflammatory Muscle Disease, Inflammatory Muscle Diseases, Inflammatory Myopathies, Inflammatory Myopathies, Idiopathic, Inflammatory Myopathy, Idiopathic, Inflammatory disorder of muscle, Inflammatory myopathy, MUSCLE DIS INFLAMM, MUSCLE/LIGAMENT DIS NOS, MYALGIA AND MYOSITIS NOS, MYOPATHIES IDIOPATHIC INFLAMM, MYOPATHY INFLAMM, MYOSITIS INFECT, Muscle Disease, Inflammatory, Muscle Diseases, Inflammatory, Muscle inflammation, Mylagia and myositis, unspecified, Myopathies, Idiopathic Inflammatory, Myopathies, Inflammatory, Myopathy, Idiopathic Inflammatory, Myopathy, Inflammatory, Myositides, Myositides, Focal, Myositides, Infectious, Myositides, Proliferative, Myositis (disorder), Myositis NOS, Myositis unspecified, Myositis unspecified (disorder), Myositis, Focal, Myositis, Infectious, Myositis, Proliferative, Proliferative Myositides, Proliferative Myositis, Unspecified disorder of muscle, ligament, and fascia, inflammation of muscle tissue, inflammatory disorder of muscle (disorder), muscle tissue inflammation, myositis
Open Targets
Disease Ontology
DOID:633
Disease Ontology
MeSH
D009220
MeSH
NCI Thesaurus
C27578
NCI Thesaurus
Highest stage of its drugs
Phase 2/3, for 3 of its 9 drugs, from ClinicalTrials.gov
Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
DANTROLENECHEMBL1201288Small moleculePhase 2/3ClinicalTrials.gov111Drugs and targets
PREDNISONECHEMBL635Small moleculePhase 2/3ClinicalTrials.gov111Drugs and targets
TELITACICEPTCHEMBL5095293ProteinPhase 2/3ClinicalTrials.gov111Drugs and targets
BARICITINIBCHEMBL2105759Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
RITUXIMABCHEMBL1201576AntibodyPhase 2ClinicalTrials.gov111Drugs and targets
TOFACITINIBCHEMBL221959Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)CHEMBL2108981Phase 1ClinicalTrials.gov110Drugs and targets
CYCLOPHOSPHAMIDECHEMBL1200796Small moleculePhase 1ClinicalTrials.gov111Drugs and targets
CORTICOTROPINCHEMBL1201610UnknownClinicalTrials.gov111Drugs and targets

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
JAK1Janus Kinase (JAK)2Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitorPhase 2https://conductscience.org/library/genes/3716Drugs and targets
JAK2Janus Kinase (JAK)2Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitorPhase 2https://conductscience.org/library/genes/3717Drugs and targets
JAK3Janus Kinase (JAK)1Janus Kinase (JAK) inhibitorPhase 2https://conductscience.org/library/genes/3718Drugs and targets
MC2RAdrenocorticotropic hormone receptor1Melanocortin receptor 2 agonistUnknownhttps://conductscience.org/library/genes/4158Drugs and targets
MS4A1B-lymphocyte antigen CD201B-lymphocyte antigen CD20 binding agentPhase 2https://conductscience.org/library/genes/931Drugs and targets
NR3C1Glucocorticoid receptor1Glucocorticoid receptor agonistPhase 2/3https://conductscience.org/library/genes/2908Drugs and targets
RYR1Ryanodine receptor 11Ryanodine receptor 1 antagonistPhase 2/3https://conductscience.org/library/genes/6261Drugs and targets
RYR3Ryanodine receptor 31Ryanodine receptor 3 antagonistPhase 2/3https://conductscience.org/library/genes/6263Drugs and targets
TYK2Janus Kinase (JAK)1Janus Kinase (JAK) inhibitorPhase 2https://conductscience.org/library/genes/7297Drugs and targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00278564Stem Cell Transplantation in Idiopathic Inflammatory Myopathy DiseasesPhase 172018-08-06MYOPATHYCYCLOPHOSPHAMIDEIts record names the diseaseClinicalTrials.gov
NCT01637064Dermatomyositis and Polymyositis Registry100Dermatomyositis, PolymyositisCORTICOTROPINIts record names the diseaseClinicalTrials.gov
NCT05832034Add-on Intravenous Immunoglobulins in Early MyositisPhase 2/344Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Polymyositis, MyositisPREDNISONEIts record names the diseaseClinicalTrials.gov
NCT00774462Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia GravisPhase 230Myositis, Myasthenia GravisRITUXIMABIts record names the diseaseClinicalTrials.gov
NCT07355257TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)Phase 2/330Inflammatory MyopathyTELITACICEPTIts record names the diseaseClinicalTrials.gov
NCT06966843Dantrolene in Statin-induced MyopathyPhase 2/323Statins Induced MyopathyDANTROLENEIts record names the diseaseClinicalTrials.gov
NCT05400889Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory MyopathiesPhase 210Idiopathic Inflammatory MyopathiesBARICITINIB, TOFACITINIBIts record names the diseaseClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
39873740DERIVED1PubMed
26539981DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021167

GET https://conductscience.org/api/diseases/v1/MONDO_0021167/drugs

API referenceFor AI assistants